Insider · CIK 0001772259
Jingrong Jean Cui
Files at BLSM (BlossomHill Therapeutics, Inc.). First filing -, latest -.
In brief
Jingrong Jean Cui files SEC Form 4 as CEO, president, director and 10% owner at BLSM (BlossomHill Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Jingrong Jean Cui has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | CConversion Common Stockindirect: By The Li and Cui Family Trust | +1,600,682 | - | - | 1,600,682 | Aug 10, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | CConversion Common Stockindirect: By The Li and Cui Family Trust | +113,435 | - | - | 1,714,117 | Aug 10, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | CConversion Common Stockindirect: By RongShan, LLC | +124,779 | - | - | 124,779 | Aug 10, 2026 |
| Aug 6, 2026 | BLSM BlossomHill Therapeutics, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +676,205 | $0.00 | $0 | 676,205 | Aug 10, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | CConversion Series Angel Preferred Stockderivativeindirect: By The Li and Cui Family Trust | -1,600,682 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | CConversion Series B Preferred Stockderivativeindirect: By The Li and Cui Family Trust | -113,435 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | CConversion Series B Preferred Stockderivativeindirect: By RongShan, LLC | -124,779 | - | - | 0 | Aug 10, 2026 |
Questions about Jingrong Jean Cui
Answered from the filings on this page, as of the latest one.
Is Jingrong Jean Cui buying or selling?
Jingrong Jean Cui has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Jingrong Jean Cui's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jingrong Jean Cui has 0.
Where does Jingrong Jean Cui file Form 4?
Jingrong Jean Cui has filed Form 4 at BLSM (BlossomHill Therapeutics, Inc.) as President and CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.